Related Experiment Video
Updated: Oct 25, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Zidesamtinib: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Abstract:
Zidesamtinib (Jideytro™) is a brain-penetrant, selective small-molecule inhibitor of ROS1 being developed by Nuvalent (a subsidiary of GSK) for the treatment of advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumours. ROS1 fusions are oncogenic drivers in a range of cancers and are identified in approximately 1-2% of NSCLCs. Zidesamtinib potently inhibits diverse ROS1 fusion proteins and clinically relevant ROS1 resistance mutations. Further, zidesamtinib has been shown to induce intracranial tumour regression in xenograft models. Supported by findings from the phase I/II ARROS-1 trial, in July 2026, zidesamtinib was approved in the USA for use in the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who received a prior ROS1 kinase inhibitor. This article summarises the milestones in the development of zidesamtinib leading to this first approval for advanced ROS1-positive NSCLC.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Treatment Resistant Cancers
Therapeutic Drug Monitoring: Overview and Classification